PepGen Investor Relations Material

PepGen Inc. is a biotechnology company focused on developing nucleic acid-based therapies for neuromuscular and rare genetic diseases. The company specializes in peptide-conjugated oligonucleotide therapeutics designed to enhance drug delivery and effectiveness. Its research and development efforts target conditions such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.